Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
| ▸ | USP14 | P54578 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503499 | 0.93 | MDM2 (0.45) | MEN1KMT2AFFAR1MDM2USP14 | |
| SCHEMBL503625 | 0.92 | USP14 (0.44) | MEN1SLC26A4KMT2AMAOBPTGES | |
| SCHEMBL503756 | 0.91 | USP14 (0.45) | MEN1KMT2APTGDR2PTGESFFAR1 | |
| SCHEMBL333497 | 0.90 | USP14 (0.44) | MEN1KMT2APTGDR2PTGESFFAR1 | |
| SCHEMBL504142 | 0.89 | MEN1 (0.44) | MEN1SLC26A4KMT2AMAOBPTGDR2 | |
| SCHEMBL335371 | 0.89 | USP14 (0.41) | PTGDR2PTGESFFAR1MDM2USP14 | |
| SCHEMBL503475 | 0.88 | KMT2A (0.43) | MEN1KMT2APTGESFFAR1ANO1 | |
| SCHEMBL503871 | 0.88 | MEN1 (0.48) | MEN1KMT2APTGESFFAR1ANO1 | |
| SCHEMBL503872 | 0.87 | USP14 (0.48) | MEN1KMT2AALOX5PTGDR2PTGES | |
| SCHEMBL503612 | 0.86 | NPC1 (0.41) | MEN1SLC26A4KMT2ARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | MEN1 2934/4885SLC26A4 2206/4885KMT2A 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.